WuXi Biologics (Cayman)
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
3.583.062.821.57
Price/Sales ratio
N/AN/AN/AN/A
Earnings per Share (EPS)
$2.17$2.54$2.76$4.94

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
888.82877.21296.05110.9559.9177.24427.85193.36102.8968.4351.9577.24
Price/Sales ratio
112.4370.0942.2317.3114.9019.65128.7563.6729.7813.6517.1014.90
Price/Book Value ratio
100.34267.42154.446.964.726.1235.1320.2912.975.765.104.72
Price/Cash Flow ratio
1.73K364.38509.9077.8049.6064.82384.10190.9582.0749.8451.3049.60
Price/Free Cash Flow ratio
-1.26K-171.83-120.39-90.32-65.25-39.10-174.39-212.97-1.39K532.13-56.94-65.25
Price/Earnings Growth ratio
N/A144.441.36-20.440.571.127.222.183.33-2.500.531.12
Dividend Yield
N/A0.04%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
37.14%32.44%39.34%40.80%40.15%41.63%45.13%46.92%44.03%40.08%46.92%40.15%
Operating Profit Margin
15.91%11.17%20.37%25.36%20.61%23.79%26.76%30.80%28.49%23.18%33.67%20.61%
Pretax Profit Margin
14.76%11.74%17.77%18.75%29.10%28.28%35.02%38.80%35.08%24.50%38.80%29.10%
Net Profit Margin
12.64%7.99%14.26%15.60%24.88%25.44%30.09%32.92%28.95%19.95%32.92%24.88%
Effective Tax Rate
14.35%31.94%19.76%16.81%14.53%10.32%13.89%12.13%15.07%14.45%12.13%10.32%
Return on Assets
6.59%3.28%7.10%5.20%6.71%5.75%5.83%7.69%8.91%6.00%7.13%6.71%
Return On Equity
11.28%30.48%52.16%6.27%7.88%7.93%8.21%10.49%12.61%8.42%12.53%7.88%
Return on Capital Employed
14.05%40.20%17.01%10.13%6.46%6.43%6.14%8.86%10.80%8.07%9.00%6.46%
Liquidity Ratios
Current Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A2.29N/A
Quick Ratio
0.740.450.933.374.183.222.912.161.732.541.093.22
Cash ratio
0.020.130.210.633.092.161.571.090.681.260.902.16
Days of Sales Outstanding
143.63124.70108.4570.86115.05126.15154.16116.10123.31132.51N/A126.15
Days of Inventory outstanding
58.7148.4148.05128.7154.6762.70128.50112.7797.4363.14143.2754.67
Operating Cycle
202.34173.12156.50199.58169.72188.85282.67228.87220.74195.66143.27188.85
Days of Payables Outstanding
256.47262.4863.9052.2953.1829.1776.5641.2933.9329.7966.5253.18
Cash Conversion Cycle
-54.13-89.3692.60147.29116.54159.68206.10187.58186.81165.86-31.19159.68
Debt Ratios
Debt Ratio
0.080.330.54N/AN/A0.100.080.060.050.030.250.25
Debt Equity Ratio
0.143.124.02N/AN/A0.140.120.080.070.050.340.34
Long-term Debt to Capitalization
N/AN/A0.76N/AN/A0.090.080.010.040.030.050.09
Total Debt to Capitalization
0.120.750.80N/AN/A0.120.110.070.070.050.110.12
Interest Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A88.40N/A
Cash Flow to Debt Ratio
0.380.230.07N/AN/A0.630.721.241.992.170.780.63
Company Equity Multiplier
1.719.297.331.201.171.371.401.361.411.401.371.17
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
0.060.190.080.220.300.300.330.330.360.270.330.30
Free Cash Flow / Operating Cash Flow Ratio
-1.37-2.12-4.23-0.86-0.76-1.65-2.20-0.89-0.050.09-0.90-1.65
Cash Flow Coverage Ratio
0.380.230.07N/AN/A0.630.721.241.992.170.780.63
Short Term Coverage Ratio
0.380.230.36N/AN/A2.382.451.614.198.091.382.38
Dividend Payout Ratio
N/A40.57%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A